首页> 外文期刊>Trials >Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial
【24h】

Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial

机译:草药提取物颗粒与益生菌混合物合用对肠易激综合征腹泻的影响:一项随机对照试验的研究方案

获取原文
获取外文期刊封面目录资料

摘要

Background Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS. Methods/Design The current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a 2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10 weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks). Discussion The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS. Trial registration ClinicalTrials.gov NCT01342718 .
机译:背景技术肠易激综合症(IBS)是一种慢性胃肠道疾病,其特征在于腹痛和排便习惯的改变而无器质性疾病。由于常规治疗的局限性,许多患者寻求IBS替代治疗。草药配方Gwakhyangjeonggisan(GJS)长期以来一直用于缓解传统医学中以腹泻为主的IBS(D-IBS)。包含7种细菌益生菌的Duolac7S经常用于D-IBS。尽管许多D-IBS患者同时服用了GJS和Duolac7S,但尚无研究调查GJS和Duolac7S联合治疗对D-IBS的影响。方法/设计本试验是一项随机,双盲,安慰剂对照的4组研究。经过2周的磨合期后,将60例D-IBS患者随机分配到4个组合组之一,该组由GJS(水提取颗粒,3 g /包,每天3次)和Duolac7S(粉末形式)组成,1粒胶囊,每天2次)或安慰剂,并随访2周。指定的治疗将持续8周。主要结局是能够充分缓解IBS疼痛和不适感,以及缓解患者的比例(每周一次)。次要结果是针对IBS症状(每天),生活质量(0、8和10周),肠通透性和肠道菌群组成(0和8周)的视觉模拟量表。讨论本研究旨在检查GJS和Duolac7S联合疗法对D-IBS的安全性和有效性。我们的研究为D-IBS的新治疗策略提供了临床证据。试用注册ClinicalTrials.gov NCT01342718。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号